4D Molecular Therapeutics, Inc.
FDMT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $21 | $3 | $18 |
| % Growth | -99.8% | 562.3% | -82.7% | – |
| Cost of Goods Sold | $0 | $97 | $80 | $61 |
| Gross Profit | $0 | -$76 | -$77 | -$43 |
| % Margin | 100% | -368.5% | -2,464.8% | -240.2% |
| R&D Expenses | $141 | $97 | $80 | $61 |
| G&A Expenses | $47 | $36 | $33 | $28 |
| SG&A Expenses | $47 | $36 | $33 | $28 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$97 | -$80 | -$61 |
| Operating Expenses | $188 | $36 | $33 | $28 |
| Operating Income | -$188 | -$113 | -$110 | -$71 |
| % Margin | -507,678.4% | -544.6% | -3,516.5% | -395.5% |
| Other Income/Exp. Net | $27 | $12 | $3 | $0 |
| Pre-Tax Income | -$161 | -$101 | -$107 | -$71 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$161 | -$101 | -$107 | -$71 |
| % Margin | -434,778.4% | -486.6% | -3,435.4% | -395.4% |
| EPS | -2.98 | -2.58 | -3.12 | -2.46 |
| % Growth | -15.5% | 17.3% | -26.8% | – |
| EPS Diluted | -2.98 | -2.58 | -3.12 | -2.46 |
| Weighted Avg Shares Out | 54 | 39 | 32 | 28 |
| Weighted Avg Shares Out Dil | 54 | 39 | 32 | 28 |
| Supplemental Information | – | – | – | – |
| Interest Income | $27 | $12 | $3 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $7 | $4 | $2 | $2 |
| EBITDA | -$181 | -$109 | -$108 | -$70 |
| % Margin | -489,556.8% | -524.4% | -3,439.7% | -387% |